Literature DB >> 26150206

Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Thorsten Bartsch1, Torge Rempe1, Arne Wrede2, Frank Leypoldt1,3, Wolfgang Brück2, Ortwin Adams4, Axel Rohr5, Olav Jansen5, Christian Wüthrich6, Günther Deuschl1, Igor J Koralnik6.   

Abstract

Progressive multifocal leukoencephalopathy (PML) has recently been described in psoriasis or multiple sclerosis patients treated with fumaric acid esters (fumarates), who had developed severe and long-standing lymphocytopenia (<500/mm(3) ). We report a psoriasis patient who presented with progressive neurologic dysfunction and seizures after 2.5 years of fumarate therapy. Despite absolute lymphocyte counts remaining between 500-1000/mm(3) , his CD4(+) and CD8(+) T-cell counts were markedly low. MRI showed right hemispheric and brainstem lesions and JC virus DNA was undetectable in his cerebrospinal fluid. Brain biopsy revealed typical features of PML as well as JC virus-infected neurons. Clinicians should consider PML in the differential diagnosis of fumarate-treated patients presenting with brain lesions or seizures even in the absence of severe lymphocytopenia.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26150206      PMCID: PMC4926166          DOI: 10.1002/ana.24471

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  57 in total

Review 1.  Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.

Authors:  P Gergely
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  PML in a patient treated with fumaric acid.

Authors:  Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

3.  Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells.

Authors:  M Vandermeeren; S Janssens; H Wouters; I Borghmans; M Borgers; R Beyaert; J Geysen
Journal:  J Invest Dermatol       Date:  2001-01       Impact factor: 8.551

4.  Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy.

Authors:  Christian Wüthrich; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

5.  JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.

Authors:  Raphael P Viscidi; Nina Khanna; Chen S Tan; Xiuhung Li; Lisa Jacobson; David B Clifford; Avindra Nath; Joseph B Margolick; Keerti V Shah; Hans H Hirsch; Igor J Koralnik
Journal:  Clin Infect Dis       Date:  2011-08-18       Impact factor: 9.079

Review 6.  Progressive multifocal leukoencephalopathy: why gray and white matter.

Authors:  Sarah Gheuens; Christian Wüthrich; Igor J Koralnik
Journal:  Annu Rev Pathol       Date:  2012-10-18       Impact factor: 23.472

Review 7.  A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.

Authors:  Monica E Mazda; Jared R Brosch; Andrea L Wiens; José M Bonnin; Aaron P Kamer; David H Mattson; Riley J Snook
Journal:  Int J Neurosci       Date:  2013-02-06       Impact factor: 2.292

8.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

9.  Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis.

Authors:  Robert Hoepner; Simon Faissner; Anja Klasing; Ruth Schneider; Imke Metz; Barbara Bellenberg; Carsten Lukas; Peter Altmeyer; Ralf Gold; Andrew Chan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-03-12

10.  Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Authors:  Alexis Régent; Brigitte Autran; Guislaine Carcelain; Rémi Cheynier; Benjamin Terrier; Bénédicte Charmeteau-De Muylder; Alain Krivitzky; Eric Oksenhendler; Nathalie Costedoat-Chalumeau; Pascale Hubert; Olivier Lortholary; Nicolas Dupin; Patrice Debré; Loïc Guillevin; Luc Mouthon
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

View more
  21 in total

1.  Psoriasis and Guillain-Barré Syndrome: Incidental or Associated?

Authors:  Betül Sargin; Gülcan Gürer
Journal:  Arch Rheumatol       Date:  2017-04-11       Impact factor: 1.472

Review 2.  Multiple sclerosis: Dimethyl fumarate is coming of age.

Authors:  Mar Tintoré; Jaume Sastre-Garriga
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

Review 3.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

Review 4.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

5.  Fingolimod-associated PML in a patient with prior immunosuppression.

Authors:  Tirisham V Gyang; Johanna Hamel; Andrew D Goodman; Robert A Gross; Lawrence Samkoff
Journal:  Neurology       Date:  2016-04-13       Impact factor: 9.910

Review 6.  Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Authors:  Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk
Journal:  J Neurol       Date:  2017-05-23       Impact factor: 4.849

Review 7.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

Review 8.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

Review 9.  Oral Therapies for Multiple Sclerosis.

Authors:  Simon Faissner; Ralf Gold
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

10.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.